1. Home
  2. SNGX vs GMM Comparison

SNGX vs GMM Comparison

Compare SNGX & GMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soligenix Inc.

SNGX

Soligenix Inc.

N/A

Current Price

$0.34

Market Cap

7.6M

Sector

Health Care

ML Signal

N/A

Logo Global Mofy Metaverse Limited

GMM

Global Mofy Metaverse Limited

N/A

Current Price

$1.02

Market Cap

7.2M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SNGX
GMM
Founded
1987
2017
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
7.2M
IPO Year
2006
2022

Fundamental Metrics

Financial Performance
Metric
SNGX
GMM
Price
$0.34
$1.02
Analyst Decision
Analyst Count
0
0
Target Price
★ $1.38
N/A
AVG Volume (30 Days)
★ 102.4K
20.1K
Earning Date
11-06-2026
07-28-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 57.03
N/A
EPS
N/A
★ N/A
Revenue
★ $119,371.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$0.06
52 Week High
$3.39
$5.79

Technical Indicators

Market Signals
Indicator
SNGX
GMM
Relative Strength Index (RSI) 35.83 37.47
Support Level $0.32 $0.97
Resistance Level $0.82 $1.22
Average True Range (ATR) 0.02 0.14
MACD 0.01 0.03
Stochastic Oscillator 26.22 54.23

Price Performance

Historical Comparison
SNGX
GMM

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

About GMM Global Mofy Metaverse Limited

Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital asset development for the metaverse industry. The Company leverages its proprietary Mofy Lab technology platform, which integrates three-dimensional (3D) reconstruction technology and artificial intelligence (AI) interactive technology, to create high-definition virtual versions of physical world objects, including humans, animals, and scenes. It provides comprehensive technology solutions to support virtual content production for use across movies, television series, animation, advertising, and gaming. The Company operates through Virtual Technology Services, which generates the majority of revenue, and Digital Asset Development and others.

Share on Social Networks: